 |
| Tumor Treating Fields Market Size |
The tumor treating fields market comprises electric field-based medical devices
used in cancer treatment. Tumor treating fields therapy uses alternating electric
fields to disrupt cancer cell division and proliferation. It works by
interfering with normal cell division activities such as alignment and movement
of internal cell structures called mitotic spindles. This disrupts the orderly
process by which normal healthy cells divide and grow, resulting in cancer cell
death. Tumor treating fields are delivered through non-invasive transducer
arrays placed on the patient's skin. They enable the delivery of low-intensity
and intermediate frequency alternating electric fields to the tumor region. The
therapy provides additional therapy option as adjuvant treatment for recurrent
glioblastoma and mesothelioma.
The global tumor treating fields market is estimated
to be valued at US$ 384.54 million in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period
2024 to 2030.
Key Takeaways
Key players operating in the Tumor
Treating Fields Market Size are Tier 1 Companies (DS Smith PLC, Crown
Holdings Inc., Ardagh Group, WestRock Co., Owens-Illinois Inc., International
Paper Company Inc., Amcor PLC, Delta Global, GPA Global), and Tier 2 Companies
(HH Deluxe Packaging, Prestige Packaging Industries, Pendragon Presentation
Packaging, Stolzle Glass Group, Keenpac, Elegant Packaging, BC Boncor, Luxpac
Ltd, McLaren Packaging Ltd, and B Smith Packaging Ltd). The companies are
investing in new product development and expansion strategies to strengthen
their market position.
The increasing prevalence of cancer worldwide presents considerable
opportunities for tumor treating fields therapy adoption. Factors such as
better outcomes with tumor treating fields adjuvant therapy for glioblastoma,
approval for additional cancer indications, and ongoing clinical trials
assessing efficacy in other cancers are expected to drive the market growth.
The major players are focused on expanding their geographic presence globally.
For instance, Novocure is establishing reimbursement pathways and clinical
access programs across Europe, Asia Pacific, and Latin America to commercialize
Optune for additional cancer types like pancreatic cancer.
Market Drivers
Rising prevalence of cancer worldwide is a major factor augmenting the demand
for tumor treating fields therapy. According to Globe Cancer, cancer burden is
expected to grow to 27.5 million new cases and 16.3 million cancer deaths by
2040. Additionally, growing geriatric population prone to cancer also drives
the market growth. For example, in 2040, one in every six people globally will
be over age 65.
Market Restraints
High cost of tumor treating fields devices and therapy is identified as a major
challenge restricting market penetration in price-sensitive regions. Optune
device alone costs over $20,000 per month of treatment. Additional monthly
costs are incurred for transducer arrays. Such high treatment costs pose
affordability issues for a section of the population in developing countries.
Segment Analysis
The tumor treating fields market is dominated by the Glioblastoma segment.
Glioblastoma is the most common and aggressive type of primary brain tumor in
humans. It accounts for about 15% of all primary brain tumors and close to 54%
of all gliomas diagnosed. Glioblastomas are Grade IV astrocytomas which mean
they are fast-growing and highly invasive. Due to the aggressiveness and lethality
of glioblastomas, tumor treating fields therapy has emerged as a standard
treatment option for newly diagnosed as well as recurrent glioblastoma. This
has predominantly driven the growth of the glioblastoma segment in the tumor
treating fields market.
Global Analysis
Regionally, North America commanded the largest share in the tumor treating
fields market in 2024 owing to advanced healthcare facilities, favorable
reimbursements for tumor treating fields therapy, and presence of prominent
players in the region. The Asia Pacific region is anticipated to witness the
highest growth during the forecast period driven by growing incidences of brain
cancers and economic growth of countries like China and India enabling greater
access to advanced tumor treatment options. Stringent regulations and pricing
pressures in Europe may hamper the market growth to some extent. However,
advantages of tumor treating fields therapy over chemotherapy are likely to
drive its adoption across major countries.
Get More Insights On This Topic: Tumor
Treating Fields Market